Abstract: A composition includes aluminum hydroxide gel and a conjugate of at least one CysA13(33-40) peptide linked to the keyhole limpet hemocyanin (KLH). Maleimidobutyric acid Nhydroxysuccinimide ester (SM) serves as cross-linking agent. The composition can produce an effective and specific immune response against A?40. The antibodies produced are specific for A?40 without significantly binding to A?42. The composition can increase the response against A?40 compared with the response produced by other conjugates that include CysA?(33-40) peptide and KLH, and are bound or conjugated by other crosslinking agents.

Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.

Abstract: The invention relates to methods for the diagnostic of a neurodegenerative disease, for the detection of a stage prior to a neurodegenerative disease or for distinguishing neurodegenerative disease from a stage prior to a neurodegenerative disease based on the level of certain pools of amyloid beta peptides which are either bound to plasma components or bound to blood cells as well as on certain calculated parameters which are obtained by an arithmetic combination of one or more of the amyloid peptide levels. The invention relates as well to kits for carrying out the above method.

Abstract: A composition includes aluminum hydroxide gel and a conjugate of at least one CysA13(33-40) peptide linked to the keyhole limpet hemocyanin (KLH). Maleimidobutyric acid Nhydroxysuccinimide ester (SM) serves as cross-linking agent. The composition can produce an effective and specific immune response against A?40. The antibodies produced are specific for A?40 without significantly binding to A?42. The composition can increase the response against A?40 compared with the response produced by other conjugates that include CysA?(33-40) peptide and KLH, and are bound or conjugated by other crosslinking agents.

Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.

Abstract: The invention relates to immunoassays which allow the detection of polypeptides in samples with a higher sensitivity than assays of the state of the art. The invention also relates to kits which provide the components needed for carrying out said immunoassays.

Abstract: A composition includes aluminum hydroxide gel and a conjugate of at least one CysA13(33-40) peptide linked to the keyhole limpet hemocyanin (KLH). Maleimidobutyric acid Nhydroxysuccinimide ester (SM) serves as cross-linking agent. The composition can produce an effective and specific immune response against A?40. The antibodies produced are specific for A?40 without significantly binding to A?42. The composition can increase the response against A?40 compared with the response produced by other conjugates that include CysA?(33-40) peptide and KLH, and are bound or conjugated by other crosslinking agents.

Abstract: The invention relates to the field of immunoassays which allow the detection of A? 17 peptides by virtue of the use of an anti-A? 17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.

Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.

Abstract: The invention relates to the field of immunoassays which allow the detection of A?17 peptides by virtue of the use of an anti-A?17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.

Abstract: The invention relates to the field of immunoassays which allow the detection of A?17 peptides by virtue of the use of an anti-A?17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.

Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.

Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.

Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.

Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, A?40 and A?42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.

Abstract: The invention relates to the field of immunoassays which allow the detection of A? 17 peptides by virtue of the use of an anti-A? 17 antibody and a kit and method using said antibody. The invention also relates to a method for diagnosing or distinguishing between different stages of a neurodegenerative disease.

Abstract: The invention relates to methods for the diagnostic of a neurodegenerative disease, for the detection of a stage prior to a neurodegenerative disease or for distinguishing neurodegenerative disease from a stage prior to a neurodegenerative disease based on the level of certain pools of amyloid beta peptides which are either bound to plasma components or bound to blood cells as well as on certain calculated parameters which are obtained by an arithmetic combination of one or more of the amyloid peptide levels. The invention relates as well to kits for carrying out the above method.

Abstract: The invention provides conjugates comprising albumin and a peptide derived from the C-terminal region of amyloid beta peptide, as well as uses thereof for the treatment of diseases characterized by the deposition of amyloid proteins and, in particular, for the treatment of Alzheimer's disease.

Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Ab40 and Ab42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.

Abstract: The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Ab40 and Ab42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease.